NEW BRUNSWICK, N.J.,
Dec. 19, 2017 /PRNewswire/ -- Johnson
& Johnson (NYSE: JNJ) will host a conference call for investors
at 8:30 a.m. (Eastern Time) on
Tuesday, January 23rd, to review fourth-quarter
results. Alex Gorsky, Chairman
and Chief Executive Officer; Dominic
Caruso, Executive Vice President, Chief Financial Officer
and Joseph J. Wolk, Vice President,
Investor Relations, will host the call.
Investors and other interested parties can access the
webcast/conference call in the following ways:
- The webcast is accessible at Johnson & Johnson's website:
www.investor.jnj.com. A webcast will be available approximately
three hours after the conference call concludes.
- By telephone: for both "listen-only" participants and
those financial analysts who wish to take part in the
question-and-answer portion of the call, the telephone dial-in
number in the U.S. is 877-869-3847. For participants outside
the U.S., the dial-in number is 201-689-8261.
- A replay of the conference call will be available until
approximately 12:00 a.m. on
January 31, 2018. The replay dial-in
number for U.S. participants is 877-660-6853. For participants
outside the U.S., the replay dial-in number is 201-612-7415. The
replay conference ID number for all callers is 13674606.
- Presentation materials will be available on
www.investor.jnj.com.
- The press release will be available at approximately
6:45 a.m. (Eastern Time) the morning
of the conference call.
About Johnson & Johnson
Caring for the world, one person at a time, inspires and unites
the people of Johnson & Johnson. We embrace research and
science - bringing innovative ideas, products and services to
advance the health and well-being of people. Our approximately
132,500 employees at more than 250 Johnson & Johnson operating
companies work with partners in health care to touch the lives of
over a billion people every day, throughout the world.
View original content with
multimedia:http://www.prnewswire.com/news-releases/johnson--johnson-to-host-investor-conference-call-on-fourth-quarter-results-300573121.html
SOURCE Johnson & Johnson